Syndromic multiplex diagnostics market to reach $5.42 billion by 2030

The Business Research Company says the syndromic multiplex diagnostics market will grow from $3.43 billion in 2025 to $3.76 billion in 2026, then hit $5.42 billion by 2030. The report points to rising infectious disease burden, faster testing demand and wider use of AI, cloud tools and automated lab systems as the main drivers.

Why it matters: - Syndromic multiplex diagnostics can identify multiple pathogens or biomarkers from one patient sample, helping clinicians reach faster diagnoses. - The technology matters most where infectious disease cases are rising and treatment decisions depend on speed and accuracy. - The market outlook points to continued demand for tools that can improve lab workflow and patient care.

What happened: - The Business Research Company released its "Syndromic Multiplex Diagnostics Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report says the market will grow from $3.43 billion in 2025 to $3.76 billion in 2026. - The forecast extends to $5.42 billion by 2030, using a 9.6% compound annual growth rate. - North America held the leading market position in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - The report links historical growth to limited access to multiplex diagnostic tools, continued reliance on single-pathogen testing, rising infectious disease burden, higher investment in clinical laboratories and early adoption of PCR-based technologies. - Future growth is tied to high-throughput multiplex platforms, AI-powered data analysis tools, expanding clinical and research laboratory networks, rapid infectious disease screening demand and connected diagnostic devices. - Forecast-period trends include greater use of multiplex PCR and nucleic acid amplification tests, expansion of next-generation sequencing applications, growth in cloud diagnostics platforms and software services, and more automated sample-to-answer systems. - Syndromic multiplex diagnostics use multiplex PCR or similar technologies to test for several likely causes of a syndrome from one sample. - The approach delivers rapid, comprehensive results and supports clinical decision-making. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also highlighted added 2026 report features, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables. - The report includes a free sample download at the sample report. - The full report is available at the full market report.

Between the lines: - The forecast reflects a broader shift toward faster, more automated diagnostic platforms as health systems face persistent infectious disease pressure. - Growth in cloud software and connected devices suggests laboratory testing is becoming more data-driven and easier to integrate across sites. - The regional split points to a mature North American market and a faster expansion runway in Asia-Pacific.

What's next: - The market is expected to keep expanding through 2030 if demand for rapid infectious disease testing and lab automation continues. - Wider adoption of next-generation sequencing, cloud diagnostics and sample-to-answer systems could shape the next phase of competition. - The report suggests Asia-Pacific will be the key growth region to watch over the forecast period.

The bottom line: - Syndromic multiplex diagnostics is moving from a niche molecular testing segment into a broader growth market built on speed, automation and multi-pathogen detection.